Selegiline Hcl Articles
Four drugmakers to pay $124 million for submission of false claims to USA’s Medicaid
20 October 2009
Wallgreens pays $35M to settle Rx fraud case
16 June 2008
Valeant slumps into 3rd-qtr $12M loss
12 November 2007
Stock Commentary - New York week to September 24, 2007
27 September 2007
Valeant's 2nd-qtr 2007 income stays constant
13 August 2007
13 new drugs added to Japan's NHI list
19 March 2007
Valeant launches Zelapar in USA
24 July 2006
Stock Commentary New York
10 December 1998
Selegiline Patch Disappoints In Alzheimer's Disease
6 November 1997
Teva Granted US Approval For Galzin
3 February 1997
Sandoz To License Orion Parkinson's Drug
4 March 1996
Somerset Pharma / Cocensys deal for Eldepryl
29 January 1996
Generics: A Passage Through Time
4 September 1995
Watson And Circa To Merge
24 July 1995
Pharmavenes Eldepryl
5 June 1995
NEW YORK STOCK COMMENT
22 May 1995
Watson Offers $606.5 Million For Circa
10 April 1995
End Of Year Encouraging For US Companies
6 February 1995
Lower Earnings For Some US Drugmakers In 3rd Qtr
7 November 1994
DEPRENYL STOCK SLIDES ON RULING
2 May 1994
ELF SANOFI CONTINUING TO BUILD IN EASTERN EUROPE
28 March 1994
DEPRENYL ACQUIRES PARKINSON'S DRUG
28 February 1994
NOVOPHARM DEAL
20 December 1993
DEPRENYL BUYER GOLDFARB DROPS OUT
6 December 1993
APOTEX SUES DEPRENYL FOUNDER
19 July 1993
STRONG GROWTH BY US PHARMA COs IN 1st QTR
10 May 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
NEW MAOIs: NOT SELECTIVE ENOUGH
8 March 1993
DEPRENYL "REMAINS ON TRACK"
15 February 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
DEPRENYL'S ELDEPRYL IN ONTARIO DRUG BENEFIT PLAN
4 January 1993
1991 MARKED SIGNIFICANT YEAR FOR DEPRENYL
4 May 1992
CANGUARD CLEARED OF CONTEMPT
13 April 1992
FURTHER FALLS FOR DEPRENYL?
6 April 1992
FURTHER FALLS FOR DEPRENYL?
6 April 1992
MYLAN CLAIMS FDA DISCRIMINATION
17 February 1992
DEPRENYL TO SELL GENERIC ELDEPRYL
3 February 1992
DEPRENYL SETTLES
27 January 1992
Showing 1-39 of 39 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
